Retatrutide does not yet have dedicated cardiovascular or renal outcome trials, though Phase 3 studies evaluating these endpoints are currently enrolling participants with expected completion in 2026
Who should not take this medication
High-Performance Liquid Chromatography (HPLC) Every single production batch must be cleared by an independent testing facility via HPLC
They are not manufactured under the same controls, are not subject to regulatory inspection, and carry no assurance of identity, purity, peptide content, endotoxin level, or sterility
How PTD-DBM Works for Hair Directly activates the Wnt/-catenin pathway, which is suppressed by DHT in androgenetic alopecia Inhibits CXXC5 a negative regulator of the Wnt pathway effectively unblocking the hair growth signal Promotes the conversion of vellus hairs (thin, fine hairs) back into terminal hairs (thick, pigmented hairs) Does not directly interfere with systemic hormones, reducing the risk of sexual side effects associated with finasteride What the Research Says Research from Yonsei University in South Korea demonstrated that PTD-DBM promoted new hair growth in mice within 28 days of topical application